Long-Acting Injectable (LAI) Antipsychotics
Improving adherence and reducing relapse in schizophrenia.
Conversion protocols from oral dosing and managing the pharmacokinetics of depot formulations.
Clinical Applications
This protocol integrates findings from recent randomized controlled trials (RCTs). We advise cross-referencing with your local institutional guidelines and the associated clinical tools to calculate specific dosing parameters or risk scores.
Frequently Asked Questions
Q: When should this protocol be reconsidered?
A: If the patient exhibits significant hepatic or renal impairment, requiring immediate dose adjustments. See the Pharmacology Guide for CYP450 considerations.